Advanced Search
Dong Zhongyi, Zeng Qin, Wang Jian, Liang Jiyun, Cao Chuanhui, Huang Zhiyong, Wu Dehua. Effect of Primary Tumor Location on Postoperative Recurrence for Patients with Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2012, 39(05): 542-546. DOI: 10.3971/j.issn.1000-8578.2012.05.012
Citation: Dong Zhongyi, Zeng Qin, Wang Jian, Liang Jiyun, Cao Chuanhui, Huang Zhiyong, Wu Dehua. Effect of Primary Tumor Location on Postoperative Recurrence for Patients with Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2012, 39(05): 542-546. DOI: 10.3971/j.issn.1000-8578.2012.05.012

Effect of Primary Tumor Location on Postoperative Recurrence for Patients with Hepatocellular Carcinoma

More Information
  • Received Date: November 16, 2011
  • Revised Date: February 12, 2012
  • Objective To explore the effect of primary tumor location or combined with serum AFP on the prognosis and postoperative recurrence for patients with hepatocellular carcinoma. Methods A total of 256 patients,who underwent routine surgery and with long term follow-up from March 2005 to October 2009,were retrospectively analyzed in our study.Kaplan-Meier survival curve was used to analyze overall survival(OS) and time to recurrence(TTR) and Logrank test was used to calculate P values.Univariate and multivariate analysis of clinicopathological parameters in hepatocellular carcinoma(HCC) patients with postoperative recurrence were carried out by Cox-regression analysis. Results There was different in overall survival of HCC patients based on their primary tumor location(P=0.022).Furthermore,the group with left or double hepatic lobe tumor demonstrated a higher recurrence risk than that of patients in the group with right hepatic lobe tumor(P=0.002).In a stratified analysis,there was a significant difference in the postoperative recurrence rate under the subset of negative serum AFP(AFP<25 ng/ml)(P<0.001),whereas no difference in the subset of positive serum AFP(AFP≥25 ng/ml)(P=0.258).Univariate and multivariate analysis showed that metastasis,serum AFP and Portal vein tumor thrombus(PVTT) were 3 dependent recurrent risk factors,whereas primary tumor location was not. Conclusion Primary tumor location can be served as an important recurrent risk factor in HCC patients after hepatectomy.
  • [1]
    Ke AW,Shi GM,Zhou J,et al.Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma[J].Hepatology,2009,49(2):491-503.
    [2]
    Baek HJ,Lim SC,Kitisin K,et al.Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis[J].Hepatology,2008,48(4):1128-37.
    [3]
    Dahiya D,Wu TJ,Lee CF,et al.Minor versus major hepatic resection for small hepatocellular carcinoma(HCC) in cirrhotic patients:a 20-year experience[J].Surgery,2010,147(5):676-85.
    [4]
    Yang Y,Zhu J,Gou H,et al.Clinical significance of Cox-2,Survivin and Bcl-2 expression in hepatocellular carcinoma(HCC)[J].Med Oncol,2011,28(3):796-803.
    [5]
    Ono K,Kokubu S,Hidaka H,et al.Risk factors of delay in restoration of hepatic reserve capacity and local recurrence after radiofrequency ablation therapy for hepatocellular carcinoma(HCC)[J].Hepatol Res,2005,31(3):172-7.
    [6]
    Tarao K,Takemiya S,Tamai S,et al.Relationship between the recurrence of hepatocellular carcinoma(HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC[J].Cancer,1997,79(4):688-94.
    [7]
    Ding Y,Chen B,Wang S,et al.Overexpression of Tiam1 in hepatocellular carcinomas predicts poor prognosis of HCC patients[J].Int J Cancer,2009,124(3):653-8.
    [8]
    Xu YF,Yi Y,Qiu SJ,et al.PEBP1 downregulation is associated to poor prognosis in HCC related to hepatitis B infection[J].J Hepatol,2010,53(5):872-9.
    [9]
    Soyama A,Eguchi S,Takatsuki M,et al.Significance of the serum level of soluble E-cadherin in patients with HCC[J].Hepatogastroenterology,2008,55(85):1390-3.
    [10]
    Dvorchik I,Demetris AJ,Geller DA,et al.Prognostic models in hepatocellular carcinoma(HCC) and statistical methodologies behind them[J].Curr Pharm Des,2007,13(15):1527-32.
    [11]
    Chen XP,Qiu FZ,Wu ZD,et al.Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma[J].Ann Surg Oncol,2006,13(7):940-6.
    [12]
    Marubashi S,Dono K,Nagano H,et al.Detection of AFP mRNA-expressing cells in the peripheral blood for prediction of HCC recurrence after living donor liver transplantation[J].Transpl Int,2007,20(7):576-82.
    [13]
    Matsuda M,Asakawa M,Amemiya H,et al.Lens culinaris agglutinin-reactive fraction of AFP is a useful prognostic biomarker for survival after repeat hepatic resection for HCC[J].J Gastroenterol Hepatol,2011,26(4):731-8.
  • Related Articles

    [1]HE Yang, YANG Runfeng, ZHOU Yingying, XU Qian, YAN Hao, JIANG Lei, JIANG Xiaohui, HUANG Yi. Effect of Aprepitant on Chemotherapy-induced Adverse Reactions in Gynecological Malignancy Patients[J]. Cancer Research on Prevention and Treatment, 2018, 45(11): 913-916. DOI: 10.3971/j.issn.1000-8578.2018.18.0265
    [2]LI Daojun, XU Xinhua, ZHANG Jianyu, LI Cong. Clinical Observation of Olanzapine in Treatment of Nausea and Vomiting Caused by Opioid Analgesics[J]. Cancer Research on Prevention and Treatment, 2018, 45(5): 326-328. DOI: 10.3971/j.issn.1000-8578.2018.17.1275
    [3]DONG Shuang, WANG Jun, HU Sheng, LIAO Guoxiang, RAN Fengming. Aprepitant versus Olanzapine for Prevention of Nausea and Vomiting Induced by Multi-day Chemotherapy in Female Lung Cancer or Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2017, 44(5): 356-359. DOI: 10.3971/j.issn.1000-8578.2017.05.009
    [4]LI Quanfu, Jin gaowa, WANG Wenjuan, JIANG Caihong, DENG Shuqin, LI Hui, CHEN Feng, BAI Xiaojun, CHEN Gang, HU Yuliang, ZHAO Jun, Dalenggaowa, Wuyungaowa. Clinical Observation of Neurokinin-1 Antagonist Preventing Multiple-day Chemotherapy-induced Nausea and Vomiting[J]. Cancer Research on Prevention and Treatment, 2017, 44(4): 290-294. DOI: 10.3971/j.issn.1000-8578.2017.04.011
    [5]LV Minhao, QIN Li, LI Juntao, GUO Xuhui, LIU Fawen, CUI Shude, ZHANG Hengwei. 原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 782-788. DOI: 10.3971/j.issn.1000-8578.2015.08.007
    [6]DONG Shuang, YU Shiying. A Study of Chemotherapy-induced Nausea and Vomiting Involving Different Dosage Regimens of Cisplatin[J]. Cancer Research on Prevention and Treatment, 2013, 40(09): 890-893. DOI: 10.3971/j.issn.1000-8578.2013.09.016
    [7]Xu Lu, Li Chunlai, Li Ling. A Constructive Experimental Study on Prevention of Chemotherapy-induced Nausea and Vomiting by Ginger-partitioned Moxibustion on Acupoint of Zusanli[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 710-712. DOI: 10.3971/j.issn.1000-8578.2012.06.024
    [8]XU Shu, LI Hong, SONG Yu-hong, LI Bin, CAI Hong-bing. Clinical Comparative of Tropisetron Hydrochloride with or without Traditional Chinese Medicine Compound in Prevention of Chemotherapy-induced Nausea and Emesis[J]. Cancer Research on Prevention and Treatment, 2009, 36(09): 787-790. DOI: 10.3971/j.issn.1000-8578.2009.09.021
    [9]MA Lei, MA Hai-long, ZHAO Xu-lin, et al. A Clinical Observation of Tropisetron in Combination with Dexame thasone and Methclopramide in the prevention of High Dose Cisplatin- induced Delayed Nausea and Emesis[J]. Cancer Research on Prevention and Treatment, 2001, 28(06): 469-470. DOI: 10.3971/j.issn.1000-8578.474
    [10]Chen Zhendong, . Medroxyprogesterone Acetate with Antiemetics: Efficacy in ControllingAnorexia, Nausea and Vomiting Induced by Chemotherapy[J]. Cancer Research on Prevention and Treatment, 1996, 23(2): 102-103.

Catalog

    Article views (2309) PDF downloads (542) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return